Is Ehlers-Danlos Syndrome a Rheumatology Issue?
Ehlers-Danlos syndrome is fundamentally a genetic connective tissue disorder, not a primary rheumatologic disease, but it requires rheumatology involvement as part of multidisciplinary care due to its prominent musculoskeletal manifestations and frequent association with rheumatologic conditions.
Understanding the Classification
EDS represents a heterogeneous group of hereditary connective tissue disorders caused by pathogenic variants in genes affecting collagen formation and stability 1, 2. The condition is characterized by:
- Joint hypermobility
- Skin hyperextensibility
- Tissue fragility
- Musculoskeletal symptoms
The primary specialty ownership depends on the EDS subtype and presenting manifestations. While genetics typically establishes the diagnosis, the predominant musculoskeletal features mean rheumatologists frequently encounter and manage these patients 3, 4.
Why Rheumatology Gets Involved
Overlapping Rheumatologic Conditions
Patients with hypermobile EDS (hEDS) have significantly higher rates of concurrent rheumatologic diseases than the general population 5. When comprehensive workup is performed:
- 67.1% of hEDS patients have at least one rheumatologic condition (compared to only 9.2% with physical exam alone) 5
- HLA-B27 prevalence is 23.9% in hEDS patients versus 6.1% in the general U.S. population 5
- Associated conditions include psoriasis, ankylosing spondylitis, rheumatoid arthritis, and fibromyalgia 5
This is clinically critical because these comorbid conditions require different management strategies than EDS alone and can contribute to joint erosions if left untreated 5.
Disease Burden Comparable to Classic Rheumatologic Diseases
The functional impairment in EDS-HT is substantial and rivals established rheumatologic conditions 6:
- Physical function is significantly worse than rheumatoid arthritis patients
- Pain severity and life interference exceed RA patients
- Overall disease burden is similar to fibromyalgia 6
The Multidisciplinary Reality
EDS requires coordinated care across multiple specialties, with no single "owner" 7. The 2024 Chinese guidelines emphasize a multidisciplinary team approach involving 24 different fields 7. Recent 2025 AGA guidelines highlight that even gastroenterologists must manage EDS patients due to the 98% prevalence of gastrointestinal disorders in hEDS 8.
Specialty Involvement by Manifestation:
- Genetics: Diagnosis and molecular confirmation (except hEDS, which remains clinical) 9, 2
- Rheumatology: Joint hypermobility, chronic pain, screening for inflammatory arthropathies 5, 3
- Cardiology: Vascular complications, POTS management 8
- Orthopedics: Joint dislocations, surgical considerations 4
- Dermatology: Skin manifestations, wound healing 3
- Gastroenterology: GI dysmotility, MCAS 8
Critical Diagnostic Pitfall
The most important clinical caveat: hEDS diagnosis requires exclusion of alternative diagnoses, including genetic testing 9. In a 2025 study, 26.4% of patients meeting clinical criteria for hEDS had an alternative or additional genetic diagnosis requiring distinct management 9. Failing to perform genetic testing can miss treatable conditions masquerading as hEDS.
Practical Approach for Rheumatologists
When evaluating suspected EDS patients:
- Confirm joint hypermobility using Beighton score
- Screen for inflammatory arthropathies (HLA-B27, RF, anti-CCP, inflammatory markers) 5
- Refer for genetic testing to exclude other EDS subtypes and alternative diagnoses 9
- Assess for POTS and MCAS given high comorbidity 8
- Coordinate with other specialists based on systemic manifestations 7
Bottom line: Rheumatology is a key player in EDS management but not the sole specialty responsible. The condition's genetic basis and multisystem involvement demand collaborative care, with rheumatology addressing the prominent musculoskeletal features and screening for treatable inflammatory conditions that frequently coexist.